E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 10/20/2005 in the Prospect News Biotech Daily.

Moody's changes Guidant to direction uncertain

Moody's Investors Service said it changed the direction of its rating review of Guidant Corp.'s debt to direction uncertain from possible upgrade.

The ratings under review include the Baa1 senior notes, Baa1 unsecured bank facility and Prime-2 short-term rating.

The change is based on comments made by Johnson & Johnson during its third-quarter earnings conference call on Tuesday that lead Moody's to believe that Johnson & Johnson may not complete its merger agreement with Guidant.

Moody's said the change is also based on concerns regarding possible longer-term effects of the recent recalls of Guidant's defibrillator products and uncertainty regarding Guidant's strategy if it remains a stand-alone company.

If the acquisition occurs substantially as planned, Moody's said it could possibly upgrade the ratings.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.